Szekerczés, Tímea
Galamb, Ádám
Kocsis, Adrienn
Benczik, Márta
Takács, Tibor
Martonos, Attila
Járay, Balázs
Kiss, András
Jeney, Csaba
Nyíri, Miklós
Schaff, Zsuzsa http://orcid.org/0000-0002-6429-8059
Sobel, Gábor
Funding for this research was provided by:
Hungarian National Research and Development Fund (NKFP_07_2-SPE-SAFE, Jedlik Ányos 2. subprogram KMR_12-1-2012-0032, NKFP_07_2-SPE-SAFE, Jedlik Ányos 2. subprogram KMR_12-1-2012-0032)
Hungarian National Research Foundation (OTKA PD105019)
Article History
Received: 18 October 2017
Accepted: 30 January 2018
First Online: 13 February 2018
Compliance with Ethical Standards
:
: The authors declare that they have no conflict of interest with respect to the research, authorship, and/or publication of this article.AKo is an employee of Cellcall and NEUMANN. MB receives consultancy fees from Cellcall and NEUMANN, she is an employee of SYNLAB GenoID Laboratory, which participated in the TRACE clinical study (all related expenses were charged to Cellcall and NEUMANN). TT is a part time employee of Cellcall, he receives consultancy fees from NEUMANN, he is minority owner of NEUMANN, the inventor of the HPV detection technology described in the manuscript covering which Cellcall submitted a patent application (license now owned by NEUMANN Diagnostics Ltd.); he is a part time employee of SYNLAB GenoID Laboratory. CsJ was a former employee of Cellcall. MNy is an employee of Cellcall and NEUMANN.